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1. Introduction
Sex steroid hormones play a role in the development and control of animal tumours, partic‐
ularly in those arising in their target organs. Due to their incidence and prevalence, mamma‐
ry tumours of female dogs and cats are among the most frequently studied with focus on
the role of ovarian oestrogen and progesterone. In these tumours, sex steroid hormones
have been shown to act during the three steps of the carcinogenesis cascade: initiation, pro‐
motion and progression. Experimental data have shown the mutagenic effect of oestrogens
[1] while epidemiologic and clinical studies highlighted the role of ovarian hormones as pro‐
moters on mammary tumours in both the dog and the cat [2-9]. Finally, oestrogens and pro‐
gesterone further act during tumour progression. Their role in the last two steps of
carcinogenesis makes it possible to control the evolution of the disease.
Studies on the role of ovarian hormones during tumour progression depend on the capabili‐
ty of demonstrating the presence of oestrogen receptors (ER) and progesterone receptors
(PR) in tumours. Earlier studies on the field were published in the seventies of the 20th cen‐
tury, all related to mammary gland tumours. Some of these studies revealed the presence of
unoccupied hormone receptors in tissue homogenates from mammary tumours of dogs and
cats [10-13]. However, actual knowledge comes from the late nineties, when different
groups of researchers standardized immunohistochemical (IHC) methods of analysis for ER
and PR in feline and canine tissues [14-19]. Once the IHC analysis revealed the presence of
sex steroid hormones receptors in mammary tumours, several studied analyzed their value
as favourable prognostic indicators [18, 20-25] adding new data to the well-known similari‐
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ties between and human and animal mammary tumours [26]. However, the important role
of ER and PR as predictive factors of response to endocrine treatment of breast cancer has
been rarely analyzed in animal tumours although recent studies based on the blockade of
PR in canine mammary carcinomas and reproductive tract tumours of female and male dogs
and cats support their value in the control of these diseases [27-30].
Mammary gland tumours are the most frequent tumours in female dogs and the third in the
cat. However, they are not the only tumours known to be sex steroid-dependent. Tumours
of the reproductive tract of female and male dogs and cats and some skin appendages can
be defined as hormone-dependent on the basis of the IHC expression of ERα and PR [31,
32]. In addition, epidemiological and clinical studies support the role of steroid hormones as
tumour promoters [28]. The most common tumours in the genital tract of the bitch are be‐
nign smooth muscle tumours of the vagina, vulva and perineal skin. Their hormone-de‐
pendence is similar to that of mammary gland tumours as the majority of canine genital
tract leiomyomas express PR and also respond to neoadjuvant treatments with the PR antag‐
onist aglepristone with a reduction in size [28].
In the dog, and to a lesser extent in the cat, benign and malignant sebaceous gland neopla‐
sias are among the most common skin tumours. Studies concerning the role of sex steroid
hormones during tumour promotion and progression are scarce but do show there is ER
and PR expression in sebaceous gland tumours of dogs. Therefore, not only androgens but
also progesterone and estrogens may regulate hormone-related physiology. In fact, preclini‐
cal studies indicate partial clinical remission after chemical castration in old dogs with hepa‐
toid gland tumours and heart failure [30].
2. Methods for studying steroid hormone receptors
Immunohistochemical (IHC) methods based on antigen-antibody reactions are widely used
today to detect steroid hormone receptors in tumours. New specific antibodies have been
developed against a range of steroid hormone receptors, enabling reliable detection by ordi‐
nary light microscopy. Traditionally, however, steroid hormone receptors were detected by
biochemical assay based on the binding of radiolabelled ligands to unoccupied receptors.
Among the most commonly used biochemical techniques was the dextran-coated charcoal
(DCC) method [33], which – until the late nineties – provided all the data available on ste‐
roid hormone receptor expression in mammary carcinomas in female domestic animals. Bio‐
chemical techniques, however, were not without drawbacks: they had to be applied to
frozen tissue samples, were very expensive, needed specialised equipment and were not
widely accessible. For this reason, published research on the use of these techniques was
scanty. The development of monoclonal antibodies highly specific to oestrogen receptor
(ERα) and progesterone receptor (PR) proteins enabled the development of immunohisto‐
chemical techniques based on the binding of receptors to specific antibodies [34-37]. These
techniques offered several major advantages over biochemical methods [38-40]:
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1. They could be applied to tissue samples routinely processed for histopathology and
could be performed in the pathology laboratory, rendering them both more accessible
and less costly.
2. They provided information regarding the specific location of ER and PR, enabling anal‐
ysis of the relationship between receptor expression and tissue structures in normal
and/or tumoural mammary glands, thus avoiding the false-positive findings common
in biochemical examinations.
3. They furnished information on all the receptors present in tissue samples, irrespective
of the occupation status.
The process of standardizing IHC methods of ER and PR detection in animal tissues in‐
volved the use of commercially available antibodies raised against human antigens first as
antibodies raised against canine and feline antigens were not produced. Then, these IHC
methods for detecting ER and PR in formalin-fixed, paraffin wax-embedded tissue samples
needed to be validated before they could be routinely implemented, as stipulated by the
“National Institutes of Health Consensus Conference on Estrogen Receptors in Breast Can‐
cer” (NIHCC), held in 1979. The first step in the validation procedure was the comparison of
ER and PR detection using both biochemical and IHC techniques and the correlation of IHC
results with those of the gold-standard radioligand-binding assays in order to evaluate their
specificity and sensitivity. In 1999, Graham et al. [15] analysed ERα expression in formalin-
fixed, paraffin-embedded tissue samples from canine mammary tumours using biochemical
and IHC methods, reporting good correlation between the two. In 2000 and 2002, Martín de
las Mulas et al. [17, 19] validated the IHC method for the detection of ERα and PR detection,
respectively, in formalin-fixed, paraffin-embedded tissue samples from feline mammary tu‐
mours using the avidin-biotin-peroxidase complex (ABC) method, and compared their find‐
ings with those obtained using the DCC biochemical method; reported agreement between
the two methods was 72.7% for ERα and 95.6% for PR. The IHC technique used demonstrat‐
ed good specificity (true-negatives) and sensibility (true-positives) (Table 1).
DCC versus IHC ERα PR
SPECIFICITY 95.6% 89.4%
SENSIBILITY 47.6% 87.5%
Table 1. Specificity and sensibility of an IHC method for detecting ER and PR, versus a biochemical method (DCC) in
feline mammary carcinomas [17, 19].
Second, the NIHCC (1979) also recommended the clinical validation of technically validated
IHC methods since the presence of ER and/or PR in human breast cancer was known to be a
favourable prognostic indicator as well as a predictive marker of the response to adjuvant
hormone therapy [41, 42]. The prognostic value of the IHC expression of ERα and PR ex‐
pression in canine mammary carcinoma has been demonstrated in the dog and the cat [18,
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20-25]. Finally, preclinical and clinical studies of our group have shown that the PR antago‐
nist Aglepristone produces partial clinical remission of canine mammary carcinoma [29].
At  present,  IHC methods are  routinely  used in  a  number  of  veterinary  laboratories  for
the detection of ER and PR. However, no consensus has yet been reached regarding tis‐
sue preparation, the antibodies and techniques to be used, and the evaluation of results.
New image-analysis systems may help to objectively evaluate receptor expression and to
standardise  the results  obtained by different  pathologists  [43].  The guidelines  issued by
the American Society of  Clinical  Oncology/College of  American Pathologists  to improve
the accuracy of immunohistochemical ERα and PR testing in breast cancer and their utili‐
ty as predictive markers of  the response to hormone therapy may serve as a model for
veterinary pathologists [44].
3. Mammary gland tumours in dogs and cats
Mammary gland tumours are the most common neoplasms in female dogs and the third
most common in female cats, but are rare in other domestic animals. Between 41% and 53%
of mammary tumours in dogs and between 85% and 93% in cats are malignant. Most au‐
thors agree that these tumours account for around 50% and 17% of all neoplasms in dogs
and cats, respectively, with an incidence of 205 and 25.4 per 100.000 dogs and cats at risk.
Median age at tumour presentation is 10-12 years in both species [45]. Tumours develop al‐
most exclusively in females, appearing only rarely in males [46-48]. Breed is also a risk fac‐
tor: mammary tumours are more common in pure-bred than in mixed-breed animals, and
some breeds – including Poodles, Boxers, Beagles, a number of Spaniel breeds, and Siamese
cats – display a higher incidence than others [45, 49-51]. Other risk factors are more contro‐
versial, or have been the subject of less research: diet, exposure to radiation, family back‐
ground and individual history of benign and malignant mammary lesions. The action of
ovarian hormones – oestrogens and progesterone – on mammary gland tissue during differ‐
ent stages of development is also a risk factor associated with the development of mammary
tumours, while breeding-related factors such as parity, age at first gestation, number of
pregnancies, pseudopregnancy and changes in the oestrous cycle, do not appear to influence
the risk of developing mammary tumours, although not all authors agree on this [45].
The development of mammary tumours in female dogs and cats is clearly hormone-depend‐
ent, and they offer a good spontaneous model of human breast cancer. The preventive ef‐
fects of castration on the development of mammary tumours in both species have been
reported [52-54]. Early ovariectomy in dogs and cats has a protective effect against both be‐
nign and malignant mammary tumours, the intensity of that effect depending on the num‐
ber of cycles before spaying. In dogs spayed before the first oestrus, the risk of developing a
mammary tumour is 0.05 %, compared to 8% after the first oestrus and 26% after the second
oestrus; the protective effect of spaying disappears after the age of 2.5 years. In cats, spaying
before 6 months of age reduces the risk of mammary carcinoma by 91% with respect to un‐
spayed cats, while spaying before 1 year of age cuts the risk by 86%.
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While prolonged administration of oestrogens has not been shown to increase the incidence
of mammary tumours [55,56], administration of medroxyprogesterone acetate and proges‐
tins over a prolonged period to young female dogs increases the risk of mainly benign mam‐
mary tumours; the intensity of that risk depends on the dosage received and on the
regularity or irregularity of treatment [6]. A number of authors, however, also report an in‐
creased incidence of malignant tumours [7]. The risk of developing a malignant tumour ris‐
es following long-term experimental administration of oestrogens combined with high-dose
progestins as shown by experimental studies to analyze the effects of the pill [55, 57], and
following the administration of drugs with combined progestagenic-oestrogenic activity to
control the signs of oestrus [6-9]. Thus, prolonged administration of high-dose (125 x human
dose) of a progestational compound (lynestrenol) prompted the development of breast can‐
cer in 40% of intact treated dogs [6]. By contrast, a combined regime of low-dose progesta‐
gen+oestrogen appears to afford some protection [6]. Cats treated with synthetic progestins
or oestrogen-progestin combinations displayed a threefold higher risk of developing benign
and malignant mammary tumours than untreated cats [58].
Figure 1. Details of a canine simple carcinoma showing expression of ERα in the nucleus of luminal epithelial cells
(brown colour). ABC. 40X.
The role played by ovarian steroid hormones during tumour progression (i.e., once the tu‐
mours are detected clinically) has been studied through their expression of ERα and PR.
Early studies using biochemical methods of ERα and PR analysis showed that between 65%
and 92% of mammary tumours contain hormone receptors [17, 19]. With IHC methods, dif‐
ferential expression between benign and malignant tumours has been observed in dogs and
cats as the expression was higher in the former. However, data concerning ERα expression
in mammary carcinomas are very different among different laboratories. Thus, in the dog,
7% [59], 10% [16], 11% [14], 22% [20], 24% [15], 59% [60, 61], 87.5% [18] and 92.6% [62] of
canine mammary carcinomas have been shown to express ERα (Figure 1). Concerning PR
expression, reported data are the following: 14% [63], 33% [14], 42%-52% [62, 64], 60% [16]
and 66% [20](Figure 2). In the cat, 7% and 17% of in situ carcinomas expressed ERα and PR,
respectively [59] while invasive carcinomas expression figures range from 10% [65] to 25%
[17] for ERα and from 38.5% and 43% for PR [19, 65]. Many of these studies point to proges‐
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terone, and not oestrogens, as the sex steroid hormone driving proliferation in mammary
gland tumours as all benign tumours of the canine mammary gland and 2/3 of malignant
tumours express PR [14, 16, 20, 22].
Figure 2. Canine simple carcinoma showing PR expression in the nucleus of neoplastic epithelial cells. (brown colour).
ABC. 20X.
After the cloning of a second ER in rats and humans, designated ERβ [66, 67], it became
known that currently reported data correlated with the isoform α of ER (ERα). Our group
was the first to publish data on the expression of the second isoform of the ER (ERβ) in
mammary tissues of dogs [68], and one more study has been performed up to date [69]. ERβ
expression was observed in the ductal and acinar epithelium of normal mammary glands
and in one third of mammary tumours. Expression was greater in benign than in malignant
tumours [68]. Among malignant tumours, ERβ expression was greater in complex and
mixed tumours than in simple carcinomas, indicating that ERβ may also be a prognostic fac‐
tor of these tumours (Figure 3).
Figure 3. ERβ immunoreaction in the nucleus of neoplastic epithelial cells of canine mammary carcinoma. ABC. 20X.
The prognostic value of steroid hormone receptor activity in malignant tumours (lower risk
of relapse and metastasis, together with greater survival time) is now widely accepted after
several univariate and multivariate prognostic studies using IHC methods for detection of
ER and PR [18, 20-25]. In a study using IHC techniques to detect ER and PR expression in
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228 tumours (155 malignant and 73 benign) from 100 bitches, Martín de las Mulas et al. [20]
found that a total of 76% of tumours (96% benign and 66% malignant) expressed ERα and/or
PR. In seven cases with lymph node metastasis, both the primary tumours and their meta‐
stases were ERα and PR negative, indicating a loss of hormone influence and thus greater
aggressiveness. Expression of PR alone in 66% of malignant tumours suggested that PR
played a more important role than ERα in tumour proliferation.
Surgery  is  the  treatment  of  choice  for  feline  and canine  mammary  tumours.  Treatment
with drugs such as tamoxifen has been tested in dogs with mammary carcinoma, but is
not  recommended  due  to  their  considerable  side  effects;  these  drugs  are  therefore  not
currently in use [70].  Ovariohysterectomy (OHE) performed at  the time of  surgery does
not appear to produce any clear benefit  in dogs with mammary carcinoma [71, 72].  The
only  adjuvant  treatment  administered  at  present  is  chemotherapy,  and  results  are  not
wholly satisfactory [45].
In 1998, Cappelletti et al. [73] reported different ERα and PR counts in tumours analysed be‐
fore and after treatment with a range of drugs including tamoxifen, concluding that malig‐
nant mammary neoplasms were sensitive to steroid hormone treatment. A feline dysplasia
of the mammary gland, the feline fibroadenomatous change, is highly sensitive to Alizin®, a
PR antagonist [74, 75]. The fact that all benign tumours and two thirds of malignant tumours
in dogs express mainly PR [16, 17, 22] points to the potential use of progesterone receptor
antagonists as a neoadjuvant and/or adjuvant treatment for these tumours. A recent study
performed by our group [29] has shown that administration of the PR receptor antagonist
Aglepristone (Alizin®, Virbac, France) as neoadjuvant treatment in female dogs inhibits the
proliferation of PR-expressing mammary carcinomas. Twenty-seven non-spayed bitches
with mammary tumours were treated with Alizin® before surgical tumour removal. Tu‐
mour tissue samples were analysed before and after treatment, and PR expression was re‐
duced following treatment (36.4% versus 59.1% prior to treatment). The proliferative index
(PI) was also analysed before and after treatment, using the avidin-biotin-peroxidase com‐
plex technique and a proliferative marker (Ki67). A significant decrease in the PI was record‐
ed in tumours expressing PR, while no change was observed in those not expressing PR,
suggesting that the PR antagonist Aglepristone inhibited tumour proliferation in PR-posi‐
tive tumours by blocking the PR.
4. Female and male reproductive-tract tumours in dogs and cats
4.1. Female reproductive tract
The actual incidence of female reproductive-tract tumours is difficult to ascertain, presuma‐
bly because a significant percentage of dogs and cats are neutered [76]. These tumours may
arise in the vagina, vulva, uterus or ovaries; vulvar and vaginal tumours are the most com‐
mon (after mammary gland tumours), accounting for 2.4% to 3% of all canine neoplasms
[77, 78]. No incidence rates are available for vulvar and vaginal tumours in cats. Uterine tu‐
mours are rare in both dogs and cats, accounting for 0.3%-0.4% and 0.2%-1.5% of all canine
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and feline tumours, respectively [77, 79-84]. Ovarian tumours are also uncommon in dogs
and cats; although the true incidence is unknown, the reported incidence in intact bitches is
6.25%, thus representing 0.5% to 1.2% of all canine tumours [85, 86], while reported inci‐
dence in cats ranges from 0.7% to 3.6% [87]. The most common neoplasms in the canine fe‐
male reproductive tract are benign tumours of mesenchymal origin, classified as
leiomyomas, fibroleiomyomas, fibromas and polyps depending on the amount of connective
tissue present [88,89]. The use of markers for smooth-muscle differentiation (e.g. desmin,
calponin, smooth muscle actin) is valuable for the accurate identification of smooth muscle
involvement in tumour growth [31, 90, 91] (Figure 4).
Figure 4. Immunohistochemical detection of the smooth muscle protein calponin in a leiomymoma. Most of the tu‐
mour cells show immunoreactive products to calponin antibody in their cytoplasms (brown colour). The vascular
smooth muscle cells are also reactive (arrow) while endothelial cells are unreactive (arrowhead). ABC. 20X.
Leiomyoma is among the most common tumours of the female reproductive tract in many
domestic species. It is located primarily in the vulva and vagina, followed by the uterus and
its incidence is greater in older non-neutered bitches [77, 78]. In two different studies, all
dogs diagnosed with leiomyoma were non-neutered bitches [78, 93] and the recurrence rate
was 15% in bitches left unneutered after local excision. On the contrary, there was no recur‐
rence in any animal when ovariohysterectomy was performed at the same time as excision.
In another study [77], no leiomyomas were diagnosed in ovariectomised bitches under two
years old. These epidemiological and clinical findings support the hormone-dependent na‐
ture of leiomyomas [88]. In addition, the role of ovarian steroid hormone receptors in the
progression of female reproductive tract leiomyomas in the dog has also been demonstrat‐
ed. Thus, Millán et al. [31] performed the first study on canine leiomyomas from the repro‐
ductive tract (uterus, vagina and vulva) demonstrating the IHC expression of ERα and PR in
tumour tissue samples. Half of the leiomyomas (50%) expressed ERα and more than three
quarters (82.1%) expressed PR (Figure 5).
Finally, a pioneer study of our group reported that the expression of PR in a canine vaginal
fibroma was a predictive factor of favourable response to hormone therapy. Aglepritone at a
dose of 10 mg/kg injected at days 1, 2, 8, 15, 28 and 35 prompted a progressive reduction in
the size of the mass, which measured 9.1 x 5.4 cm on day 1 and 6.4 x 4.7 cm on day 45 [28]
(Figure 6). The authors evaluated the proliferation index in the same study using a prolifera‐
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tion marker (Ki67), recording similar low values at days 15 and 25 of treatment, suggesting
that Aglepristone did not reduce tumour size by reducing the tumour cell proliferation rate
but rather through increasing apoptosis. It was therefore concluded that the size of PR-ex‐
pressing benign tumours of the canine vagina could be reduced by palliative or neoadjuvant
therapy with the PR antagonist Aglepristone. These findings regarding steroid hormone re‐
ceptor expression in canine tumours of the female reproductive tract highlight the potential
of hormone therapy in selected cases. In cats, leiomyomas located in the mammary gland
and in the perineal region are reported to express ERα and PR [27]; however, no research
has yet focussed on the expression of steroid hormone receptors in feline leiomyomas locat‐
ed in the vagina, vulva or uterus.
Figure 5. Immunohistochemical detection of ERα in a leiomyoma. Most of the tumour cells show immunoreactive
products to ER antibody in their nucleus (brown colour)(arrow). ABC. 40X.
Figure 6. A) Female dog with a perineal mass measuring 9.1 x 5.4 cm. (B) The appearance of the tumour mass 28 days
after treatment with aglepristone. The size is reduced to 6.4 x 4.7 cm [28].
4.2. Male reproductive tract
Male reproductive-tract tumours in dogs and cats may arise in the testes, prostate, penis or
foreskin. Testicular tumours are the second most common cancer in intact dogs, accounting
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for roughly 90% of all reproductive-tract tumours [96]. In cats, however, testicular tumours
are rare [97]. Prostate tumours are uncommon in dogs, with a reported incidence of between
0.2% to 0.6% [98, 99], and equally rare in cats [97, 100-102]. Many penis and foreskin tu‐
mours affect the epithelial surface of these structures, the most common being the transmis‐
sible venereal tumour of the penis in dogs [103].
Currently, the only male reproductive-tract tumour in domestic species for which published
data is available regarding the possible influence of steroid hormones on tumour develop‐
ment is canine prostate carcinoma. The dog is the only non-primate species that develops
spontaneous prostate cancer [104]. Most tumours in this location are of epithelial origin [98,
105] and mainly affect older dogs (average age 10 years), prostate carcinoma being common
[98]. The prostate is an androgen-dependent organ [106], and androgens achieve their effect
through activation of androgen receptors (AR). However, there is a good deal of controversy
concerning the influence of androgens on the development and biological behaviour of ma‐
lignant prostate tumours. While some studies have found no evidence that castration has a
protective effect against prostate carcinoma [99], others argue that castration before sexual
maturity reduces the risk of this malignancy [105]; still others suggest that castration may
actually increase the incidence and aggressive behaviour of canine prostate carcinomas [98].
The expression of steroid hormone receptors in tumour tissue samples of canine prostate
carcinoma has been rarely studied. The more complete study up to date showed that expres‐
sion of AR, ERα and ERβ was lower in malignant tumour epithelial cells than in normal
prostate tissue and benign lesions, suggesting that oestrogen actions in the prostate are com‐
plex and may play a dual role in the aetiology of prostate cancer [32, 107]. This study also
demonstrated for the first time that PR expression in canine prostate tumours is greater than
in normal prostate tissue [32], although the effect of progesterone at this location still re‐
mains to be demonstrated, as does the potential for hormone therapy.
5. Cutaneous tumours in dogs and cats
Tumours of the skin and subcutaneous tissue are the most common neoplasms affecting
dogs and the second most common in cats [108]. Incidence rates have been estimated at
around 450 per 100,000 dogs and 120 per 100,000 cats [108]. In dogs, most skin tumours are
benign, the most frequent being histiocytomas and sebaceous gland adenomas. In cats, how‐
ever, approximately 50% to 65% of skin tumours are histologically malignant, the most fre‐
quently-reported being squamous cell carcinomas [109].
Epidemiological research has identified breed and age as major risk factors for these tu‐
mours. A number of authors note a linear increase in risk by a factor of 1.1 per year of
increasing  age;  additionally,  pure-bred  dogs  appear  to  be  twice  as  likely  to  develop  a
malignancy as cross-breeds.  When all  types of  tumours are considered together,  no sig‐
nificant sex predilection is apparent [110]. A number of etiological factors – physical, vi‐
ral,  genetic  and molecular  –  have been reported for  some skin tumours [111].  Over the
last few years, it has become increasingly evident that steroid sex hormones may play an
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important role in the pathogenesis of these tumours, as they do in mammary tumours. It
is  well  known that  oestrogens,  progesterone and androgens not  only help regulate  skin
development  and  function,  such  as  the  development  and/or  physiology  of  sebaceous
glands and hair follicles, but are also involved in the development and biological behav‐
iour of certain skin neoplasms [112].
To date, a number of studies have demonstrated a possible relationship between sex steroid
hormones and sebaceous, perianal and hepatoid gland tumours and mast-cell tumours in
domestic animals. To better understand this relationship, recent research has focussed on
pinpointing the site of action of these hormones and on locating their receptors in both nor‐
mal and tumour tissues. As a result, biochemical and immunohistochemical studies carried
out over the last few years have detected androgen receptors (AR), oestrogen receptor α
(ERα) and progesterone receptors (PR) in epidermis, hair follicles and fundamentally in the
sebaceous glands of canine skin [113-117]. These results suggest that not only androgens and
oestrogens, but also progesterone, may play a major role in the regulation of normal skin
appendage function and in the pathogenesis and development of neoplasms.
Sebaceous gland tumours are among the most common skin tumours in the dog. They can
be divided into four groups based on histological appearance: sebaceous hyperplasia, seba‐
ceous epitheliomas, sebaceous adenomas and sebaceous adenocarcinomas. They account for
between 6.8% to 7.9% of all skin tumours in dogs, and between 2.3% to 4.4% in cats [118].
Canine benign and malignant sebaceous gland neoplasias may provide a suitable experi‐
mental model for the study of hormone influences on the development of glandular tu‐
mours [114]. As in human skin, specific staining for ERα and PR is seen mainly in the basal
cells of normal sebaceous glands [115-117]. However, unlike in human medicine, no data are
available regarding the possible involvement of these steroid sex hormones in the pathology
of canine and feline skin and the development of cutaneous neoplasms. A single study by
the present authors analysed ERα and PR expression in canine sebaceous gland hyperpla‐
sias, adenomas/epitheliomas and carcinomas [117], revealing that canine sebaceous glands
express both ERα and PR (Figure 7 y 8). Moreover, differences were recorded between types
of lesion in the number of cells expressing ERα and PR. Compared with normal sebaceous
glands, ERα expression was significantly lower in sebaceous gland epitheliomas and adeno‐
carcinomas, suggesting that ERα plays a key physiological role in the maintenance of nor‐
mal sebaceous glands, and that a decrease in levels influences the development of both
benign and malignant neoplasms. A number of studies indicate that this drop in ERα could
be secondary to changes in androgen or oestrogen production, but further research is re‐
quired to confirm this hypothesis in canine sebaceous glands. The cited study also found
that PR expression in adenocarcinomas was significantly lower than in normal and hyper‐
plastic sebaceous glands, suggesting that tumour growth may become less hormone-de‐
pendent during the progression phase of carcinogenesis, as reported in certain human
mammary tumours. Unlike ERα, the proportion of PR-positive cells did not differ signifi‐
cantly from that found in normal sebaceous glands, a finding also reported in humans [112].
This may indicate that progesterone does not necessarily influence the growth of this type of
tumours. Conversely, sebaceous gland carcinomas display a significant loss in PR staining
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intensity; PR loss may be one factor involved in the pathogenesis of canine sebaceous gland
neoplasms.
Figure 7. Immunohistochemical localization of PR in sebaceous gland hyperplasia. Nuclear staining is observed in bas‐
al cells (arrow) and differentiated sebocytes (arrowhead) [117]. ABC. 40X.
Figure 8. Immunohistochemical localization of PR in a sebaceous gland epithelioma. Nuclear staining is observed in
basal cells (arrow) and differentiated sebocytes (arrowhead) [117]. ABC. 40X.
The influence of female sex steroids on their receptors in skin has been highlighted by sever‐
al studies. When an ovariectomised bitch received a local estradiol (E2) implant, ER levels in
the affected skin were found to be six times higher than in control skin [119]. However, de‐
spite the considerable amount of work done to date in this field, further research is still re‐
quired to demonstrate the presence of AR and examine of the effects of these hormones and
their pharmacological antagonists on tumour development.
Other tumours considered clearly hormone-dependent include those arising in the peria‐
nal  or  hepatoid  glands,  modified  sebaceous  glands  located  in  the  perianal  dermis.  The
most frequently observed tumours of this region in dogs are perianal adenoma, perianal
adenocarcinoma and apocrine gland adenocarcinoma of the anal sac.  Perianal adenomas
account  for  between  58% and 96% of  all  canine  perianal  tumours  [120].  Unlike  adeno‐
mas, perianal gland carcinomas are rare, accounting for between 3% and 17% of all per‐
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ianal  neoplasms  [121].  Although  found  in  both  male  and  female  dogs,  the  highest
incidence is reported in intact males of mean age 10 or more [122]. This evidence has for
years been interpreted as proof of a clear stimulation of tumour development by sex ste‐
roid hormones, particularly androgens [123]. Adenomas have been found to be hormone-
responsive;  a  full  or  partial  regression  has  been  observed  following  castration  or
oestrogen  treatment  [113,  120,  124].  In  females,  perianal  adenomas  occur  almost  exclu‐
sively in ovariohysterectomised animals  whose low oestrogen levels  fail  to  suppress tu‐
mour  growth.  Similarly,  testicular  interstitial  cell  tumours  –  which  clinical  observation
suggests  are  associated  with  an  increase  in  systemic  androgen levels  –  occur  more  fre‐
quently in association with perianal tumours [125]. While hormone dependence has been
clearly  demonstrated in  the  case  of  perianal  adenomas,  there  appears  to  be  no link be‐
tween  perianal  adenocarcinomas  and  steroid  sex  hormones.  Perianal  gland  carcinomas
do not regress following castration and are not responsive to hormone therapy with oes‐
trogens  [121,  124].  However,  receptors  for  these  hormones  have  been found in  normal,
hyperplastic and neoplastic perianal glands in dogs (Figure 9). An early report identified
androgen-binding sites in perianal adenomas [124]. Research by Pisani et al.  [126] detect‐
ed  AR  expression  in  all  normal  and  abnormal  glands,  although  in  hyperplastic  tissues
the proportion of positive nuclei was significantly greater than in normal tissue. A simi‐
lar  increase  in  the  percentage  of  positive-staining  nuclei  was  also  observed  in  perianal
epitheliomas,  while  in  adenomas  the  increase  with  respect  to  normal  tissue  was  only
slight.  In  adenocarcinomas,  the  proportion  of  AR-positive  cells  was  similar  to  that  ob‐
served in benign tumours.
Figure 9. Immunohistochemical localization of ERα in a hepatoid gland adenoma. Nuclear staining is observed in bas‐
al cells (arrow) and differentiated hepatoid cells (arrowhead). ABC. 20X.
All these observations support the view that therapy based on antagonists of these hor‐
mones could prove beneficial in the treatment of these tumours. The present authors have
carried out a preliminary clinical trial in order to evaluate the effect of Deslorelin (Suprelor‐
inTM Virbac), a GnRH antagonist, on the clinical response of perianal gland adenomas [127].
This antagonist suppresses pituitary production of the hormones LH and FSH and of steroid
sex hormones; its effect has been compared to that of surgical castration. The trial found that
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subcutaneous deslorelin implants induced complete remission in at least 50% of dogs and a
partial response to treatment in a further 29%. This antagonist could thus be considered as a
new option for the treatment of perianal gland adenomas.
Finally, the association between mast-cell tumours (MCTs) and steroid sex hormones re‐
mains controversial. The role of these hormones in tumour pathogenesis is poorly under‐
stood, although some evidence is now available: one study has detected cytosolic receptors
for oestrogen and progesterone in canine MCTs [127], while another found that 6 out of 9
MCTs contained no ERα and 3 were questionable [128].
6. Conclusion
Sex steroid hormones are involved in the development of animal tumours with high epide‐
miological and clinical impact. Research in the field has shown the potential benefits of en‐
docrine manipulations to control tumour progression in a neoadjuvant or adjuvant setting.
From a comparative point of view, steroid hormone dependent animal tumors represent an
accessible and natural model of human disease.
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